| Literature DB >> 26213925 |
Stefan Bittner1, Nicole Bobak2, Majella-Sophie Hofmann3, Michael K Schuhmann4, Tobias Ruck5, Kerstin Göbel6, Wolfgang Brück7, Heinz Wiendl8, Sven G Meuth9,10.
Abstract
Lymphocytes express potassium channels that regulate physiological cell functions, such as activation, proliferation and migration. Expression levels of K2P5.1 (TASK2; KCNK5) channels belonging to the family of two-pore domain potassium channels have previously been correlated to the activity of autoreactive T lymphocytes in patients with multiple sclerosis and rheumatoid arthritis. In humans, K2P5.1 channels are upregulated upon T cell stimulation and influence T cell effector functions. However, a further clinical translation of targeting K2P5.1 is currently hampered by a lack of highly selective inhibitors, making it necessary to evaluate the impact of KCNK5 in established preclinical animal disease models. We here demonstrate that K2P5.1 knockout (K2P5.1-/-) mice display no significant alterations concerning T cell cytokine production, proliferation rates, surface marker molecules or signaling pathways. In an experimental model of autoimmune neuroinflammation, K2P5.1-/- mice show a comparable disease course to wild-type animals and no major changes in the peripheral immune system or CNS compartment. A compensatory upregulation of the potassium channels K2P3.1 and KV1.3 seems to counterbalance the deletion of K2P5.1. As an alternative model mimicking autoimmune neuroinflammation, experimental autoimmune encephalomyelitis in the common marmoset has been proposed, especially for testing the efficacy of new potential drugs. Initial experiments show that K2P5.1 is functionally expressed on marmoset T lymphocytes, opening up the possibility for assessing future K2P5.1-targeting drugs.Entities:
Keywords: EAE; K2P channels; K2P5.1; KCNK5; TASK2; autoimmune neuroinflammation; ion channels; multiple sclerosis; potassium channels
Mesh:
Substances:
Year: 2015 PMID: 26213925 PMCID: PMC4581175 DOI: 10.3390/ijms160816880
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1K/ and WT mice showed a comparable clinical, immunological and histopathological phenotype in MOG35–55 EAE. (A) Upon MOG35-55 immunization, K/ mice showed a comparable clinical disease course (left panel) and cumulative EAE score (right panel) over 30 days compared to wild-type mice (three independent immunizations, each n = 7–8); (B–D) Splenocytes from immunized mice were isolated at disease maximum (d16) and restimulated with 10 µg/mL MOG35–55 peptide. No differences were observed for (B,C) proliferation assessed by two independent methods and for (D) the production of IFNγ, IL-2 and IL-17 (n = 4); (E) Flow-cytometric evaluation of CNS-infiltrating immune cells isolated at disease maximum revealed no significant changes for numbers of CD4+, CD8+ and CD11b+ cells (n = 4); (F) Histological evaluation of inflammatory infiltrates (HE staining, upper panel) and demyelinated area (Luxol fast blue (LFB) staining, lower panel) showed no significant differences (n = 4–5). Scale bar (100 µm) accounts for all images. ns = not significant.
Figure 2T lymphocytes from K/ mice displayed no obvious differences in immune cell function (A,B). (A) Human, but not (B) mouse CD4+ T lymphocytes show an upregulation of K2P5.1 (left panel: mean ΔCt values; middle panel: all donors are displayed separately; right panel: relative expression); (C) K2P5.1 expression can be detected by Western blotting in splenocytes and kidney tissue from wild-type, but not from K/ (ko) mice (representative examples); (D) WT and K/ splenocytes show no differences in cytokine production (n = 6); (E) No significant differences were observed for proliferation rates from WT and K/ T lymphocytes (left panel: proliferation assay; right panel: flow cytometry-based assessment of cell cycle stages; n = 8); (F) Splenocytes from WT and K/ display a comparable immune cell composition (n = 6); (G) WT and K/ thymi are comparable concerning proportions of double-negative, double-positive and CD4+/CD8+ single-positive cells (n = 4, one representative example is shown); (H,I) CD4+ T lymphocytes from WT and K/ mice show no significant alterations concerning (H) memory cell composition (I) and activation and migration markers (n = 5). ns = not significant; **p < 0.05.
Figure 3K deletion results in a compensatory upregulation of K2P3.1 and KV1.3. (A) Relative quantification of unstimulated and stimulated WT and K/ CD4+ and CD8+ T lymphocytes for the expression of K, K, K and K (n = 5–6); (B) Electrophysiological assessment of the resting membrane potential of unstimulated CD4+ T lymphocytes (n = 10); (C) Voltage steps from −80 to +40 mV for 500 ms were used to record outward currents in stimulated WT and K/ CD4+ T lymphocytes. Current reduction after application of the K2P3.1 inhibitor A293 (10 µM) and the KV1.3 inhibitor Shk (10 nM) (n = 4) is shown; (D) Naive WT and Task2/ CD4+ T lymphocytes were stimulated for 10 min either with CD3/CD28 antibodies or PMA followed by cell lysis and Western blot analysis with antibodies against phosphorylated Zap70 (p-Zap70, left panel) and ERK1/2 (right panel). Representative examples (upper panel) and quantitative evaluation (lower panel, n = 4) are shown; (E) Calcium imaging experiments using Fura-2 in WT and Task2/ CD4+ T lymphocytes were performed under two conditions: T cell-receptor crosslink (CD3-X) in 2 mM Ca2+ (upper panel) or application of thapsigargin (TG) for intracellular Ca2+ store depletion in 0 mM Ca2+ prior to switching to 2 mM Ca2+ solution (lower panel). One out of five representative measurements are shown. ns = not significant; ** p < 0.05.
Evaluation of commercial kits for marmoset research.
| Commercial Kit | Company | Functional | Not Functional |
|---|---|---|---|
| CD4 non-human primate MACS kit | Miltenyi Biotec | X | |
| CD8 non-human primate MACS kit | Miltenyi Biotec | X | |
| Mouse anti-human CD4 antibody (RPA-T4) | BioLegend | X | |
| Mouse anti-human CD8 antibody (RPA-T8) | BioLegend | X | |
| Human CD3/CD28 microbeads | Life Technologies | X | |
| Mouse CD3/CD28 microbeads | Life Technologies | X | |
| Phytohemagglutinin | Sigma-Aldrich | X | |
| ATP Assay | PerkinElmer | X | |
| Rabbit anti-human/mouse K2P5.1 | Sigma-Aldrich | X | |
| Cytokine flow cytomix | BenderMed Systems | X | |
| Human ELISA IFNγ, IL-2 | eBioscience, RD Systems | X | |
| Mouse ELISA IFNγ, IL-2 | eBioscience, RD Systems | X | |
| Human RT-PCR primers | Applied Biosystems | X | |
| Quinidine | Sigma-Aldrich | X |
Different commercial kits were evaluated with marmoset cells and are marked either as functional or as non-functional (“X” are set when applicable). See the Experimental Section for further details.
Figure 4Expression of K2P5.1 channels in immune cells and CNS neurons in the common marmoset. (A) RT-PCR experiments show that CD4+ T lymphocytes from the common marmoset express K in RT-PCR experiments, which is upregulated upon stimulation with PHA (n = 3); (B) CD4+ and CD8+ T lymphocytes express K2P5.1 protein as assessed by flow cytometry (one representative example out of three is shown); (C) The K2P5.1 inhibitor quinidine (20 µM) reduces the proliferation of stimulated marmoset CD4+ T lymphocytes (n = 3); (D) EAE lesions in the common marmoset characterized by HE, CD3 and LFB staining; (E) Brain samples from naive common marmosets were assessed by immunohistochemical staining for K2P2.1, K2P5.1 and K2P9.1. NeuN was used as a neuronal marker. The region of interest is displayed by HE staining on the right side. * = p < 0.05.